Emergent Biosolutions EBS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Commercial Products | $42.9M+11.7% | $38.4M-48.7% | $74.9M+11.0% | $67.5M+49.0% | $45.3M-30.4% | |
| MCM Products | $101.8M+2.6% | $99.2M-30.4% | $142.5M+144% | $58.4M-62.7% | $156.6M+34.1% | |
| Total revenues by Product | ||||||
| All other revenue | $11.4M+2.7% | $11.1M-19.0% | $13.7M-8.7% | $15M-26.1% | $20.3M+58.6% | |
| Commercial Product sales | $42.9M+11.7% | $38.4M-48.7% | $74.9M+11.0% | $67.5M+49.0% | $45.3M-30.4% | |
| MCM Product sales | $101.8M+2.6% | $99.2M-30.4% | $142.5M+144% | $58.4M-62.7% | $156.6M+34.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Emergent Biosolutions break its business down?
- Emergent Biosolutions (EBS) reports total revenues by business across 2 parts — Commercial Products and MCM Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Emergent Biosolutions's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Emergent Biosolutions's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
